Terms: = Breast cancer AND CIITA, P33076, 4261, ENSG00000179583, MHC2TA, C2TA
26 results:
1. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
James JL; Taylor BC; Axelrod ML; Sun X; Guerin LN; Gonzalez-Ericsson PI; Wang Y; Sanchez V; Fahey CC; Sanders ME; Xu Y; Hodges E; Johnson DB; Balko JM
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38315170
[TBL] [Abstract] [Full Text] [Related]
2. Investigating the role of tumour-to-skin proximity in predicting nodal metastasis in breast cancer.
Sivakanthan T; Tanner J; Mahata B; Agrawal A
Breast Cancer Res Treat; 2024 May; 205(1):109-116. PubMed ID: 38308767
[TBL] [Abstract] [Full Text] [Related]
3. cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes.
Lei PJ; Pereira ER; Andersson P; Amoozgar Z; Van Wijnbergen JW; O'Melia MJ; Zhou H; Chatterjee S; Ho WW; Posada JM; Kumar AS; Morita S; Menzel L; Chung C; Ergin I; Jones D; Huang P; Beyaz S; Padera TP
J Exp Med; 2023 Sep; 220(9):. PubMed ID: 37341991
[TBL] [Abstract] [Full Text] [Related]
4. Genetic and Epigenetic Regulation of the Innate Immune Response to Gout.
de Lima JD; de Paula AGP; Yuasa BS; de Souza Smanioto CC; da Cruz Silva MC; Dos Santos PI; Prado KB; Winter Boldt AB; Braga TT
Immunol Invest; 2023 Apr; 52(3):364-397. PubMed ID: 36745138
[TBL] [Abstract] [Full Text] [Related]
5. Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.
Huang L; Liu X; Li L; Wang L; Wu N; Liu Z
Med Oncol; 2022 May; 39(5):92. PubMed ID: 35568771
[TBL] [Abstract] [Full Text] [Related]
6. Screening of osteoarthritis diagnostic markers based on immune-related genes and immune infiltration.
Yuan WH; Xie QQ; Wang KP; Shen W; Feng XF; Liu Z; Shi JT; Zhang XB; Zhang K; Deng YJ; Zhou HY
Sci Rep; 2021 Mar; 11(1):7032. PubMed ID: 33782454
[TBL] [Abstract] [Full Text] [Related]
7. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
Kagoya Y; Guo T; Yeung B; Saso K; Anczurowski M; Wang CH; Murata K; Sugata K; Saijo H; Matsunaga Y; Ohashi Y; Butler MO; Hirano N
Cancer Immunol Res; 2020 Jul; 8(7):926-936. PubMed ID: 32321775
[TBL] [Abstract] [Full Text] [Related]
8. Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells.
Medarova Z; Pantazopoulos P; Yoo B
Sci Rep; 2020 Feb; 10(1):1970. PubMed ID: 32029822
[TBL] [Abstract] [Full Text] [Related]
9. Increased Overall Mortality Even after Risk Reducing Surgery for
Öfverholm A; Einbeigi Z; Wigermo A; Holmberg E; Karsson P
Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31888263
[TBL] [Abstract] [Full Text] [Related]
10. Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults.
Yoshida A; Arai Y; Hama N; Chikuta H; Bando Y; Nakano S; Kobayashi E; Shibahara J; Fukuhara H; Komiyama M; Watanabe SI; Tamura K; Kawai A; Shibata T
Histopathology; 2020 Mar; 76(4):509-520. PubMed ID: 31647130
[TBL] [Abstract] [Full Text] [Related]
11. c-Myc induced the regulation of long non-coding RNA RHPN1-AS1 on breast cancer cell proliferation via inhibiting P53.
Zhu P; Li Y; Li P; Zhang Y; Wang X
Mol Genet Genomics; 2019 Oct; 294(5):1219-1229. PubMed ID: 31089812
[TBL] [Abstract] [Full Text] [Related]
12. Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer.
Li Y; Zhao Y; Gong C; Xie Y; Hu X; Zhang J; Wang L; Zhang S; Cao J; Tao Z; Wang B
Sci Rep; 2019 Mar; 9(1):3563. PubMed ID: 30837503
[TBL] [Abstract] [Full Text] [Related]
13. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
Shah N; Mohammad AS; Saralkar P; Sprowls SA; Vickers SD; John D; Tallman RM; Lucke-Wold BP; Jarrell KE; Pinti M; Nolan RL; Lockman PR
Pharmacol Res; 2018 Jun; 132():47-68. PubMed ID: 29604436
[TBL] [Abstract] [Full Text] [Related]
14. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like breast cancer Based on Functional Differences Using Pathway Analysis.
Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
[TBL] [Abstract] [Full Text] [Related]
15. EBP1 protein modulates the expression of human MHC class II molecules in non-hematopoietic cancer cells.
Pisapia L; Barba P; Cortese A; Cicatiello V; Morelli F; Del Pozzo G
Int J Oncol; 2015 Aug; 47(2):481-9. PubMed ID: 26081906
[TBL] [Abstract] [Full Text] [Related]
16. Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.
Mostafa AA; Codner D; Hirasawa K; Komatsu Y; Young MN; Steimle V; Drover S
PLoS One; 2014; 9(1):e87377. PubMed ID: 24475282
[TBL] [Abstract] [Full Text] [Related]
17. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract] [Full Text] [Related]
18. Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (ciita) promoter IV in breast cancer cells.
Truax AD; Thakkar M; Greer SF
PLoS One; 2012; 7(4):e36013. PubMed ID: 22563434
[TBL] [Abstract] [Full Text] [Related]
19. Negative regulation of MHC class II gene expression by CXCR4.
Sheridan C; Sadaria M; Bhat-Nakshatri P; Goulet R; Edenberg HJ; McCarthy BP; Chang CH; Srour EF; Nakshatri H
Exp Hematol; 2006 Aug; 34(8):1085-92. PubMed ID: 16863915
[TBL] [Abstract] [Full Text] [Related]
20. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
[TBL] [Abstract] [Full Text] [Related]
[Next]
